EATG » News

The Value of Health: Improving Outcomes final report was launched

Today, the The Value of Health: Improving Outcomes multi-stakeholder initiative launched its final report at the European Parliament. European AIDS Treatment Group's chair, Nikos Dedes, underlined the critical importance of…

The European AIDS Treatment Group is looking for a Financial Assistant

Type of contract: Half-time, temporary position with possibility for extension Location: Brussels, Belgium Reporting to: Executive Director Start date: As soon as possible The European AIDS Treatment Group is looking…

The European AIDS Treatment Group is looking for an Executive Director

Type of contract: Full-time, permanent contract Location: Brussels, Belgium Reporting to: Board of Directors Start date: As soon as possible in the range of October-December 2018 The European AIDS Treatment…

2nd Hep-C Community Summit: We are more than just patients

The European AIDS Treatment Group participates in the 2nd Hep-C Community Summit that takes place on the 18th of September in Lisbon. Organised by Correlation European Harm Reduction Network, the summit will…

Webinar: Patient Engagement on Medicines Research & Development

Join us for a webinar about patient engagement in the process of research and development of medicines on Thursday, September 6 from 18:00 to 19:15 CET.   Four European patient…

Open letter: UN General Assembly High Level Meeting on the fight against Tuberculosis

Few weeks before the UN General Assembly High Level Meeting on the fight against Tuberculosis, the EATG issues an open letter: 'As negotiations on the final declaration are now being…

ESTICOM: First from a series of community reports from EMIS 2017 is now online

A week ago the EATG co-chaired the satellite symposium "European surveys and trainings to improve MSM community health (ESTICOM)" at the 22nd International AIDS conference.  During this session we had…

The EATG welcomes the European Court of Justice decision to invalidate the patent extension of Truvada

Amsterdam, 26 July 2018   The European AIDS Treatment Group welcomes the landmark decision of the European Court of Justice confirming the invalidity of the patent extension (Supplementary Protection Certificate)…

EATG at the 22nd International AIDS conference: Catch up with the evidence and give our communities the services we need

Amsterdam, 23 July 2018   As an organisation led by people living with HIV/AIDS across Europe and Central Asia, working together with the several affected communities in the last 25…

AIDS 2018: Addressing research gaps identified by women living with HIV in Europe and Central Asia

We are pleased to invite you to join a side-meeting at the AIDS 2018 conference that will bring together community, clinicians and researchers to discuss research gaps related to women…

AIDS 2018: The programme and the presentations of the European Civil Society Forum booth in the Global Village

The EATG and AIDS Action Europe are co-hosting the European Civil Society Forum (booth 618) at the Global Village of the 22nd International AIDS Conference in Amsterdam. Organisations and activists…

Ageing with HIV conference outcomes: read watch and register to discuss

The EATG organised a conference titled ‘New challenges and unmet needs of people living and ageing with HIV/AIDS aged 18-50, Quality of Life and Preventive Healthcare’ from 3 to 6…

EATG’s new term as a member of the Civil Society Forum on Drugs (2018-2021)

This week the European AIDS Treatment Group participated in the first meeting of the new 3-year term of the Civil Society Forum on Drugs that took place in Brussels. The CSFD…

What is on the minds of PLHIV in Europe in terms of their long term health?

Results: Long term health perspectives of people living with HIV in Europe   The EATG in collaboration with Volle Maan Communicatie Bureau conducted a study titled ‘Long term health perspectives…

EHVA: a clinical trial for therapeutic vaccination for HIV is about to start

Today and tomorrow EATG is attending the European HIV Vaccine Alliance (EHVA) consortium meeting in Barcelona. The EATG is one of the 39 partners of the consortium that aims to develop…

Position on scaling up HIV self-testing and self-sampling

Just published - an opinion piece on scaling up HIV self-testing and self-sampling, by the HIV in Europe Initiative (a European civil society, policy makers, health professionals and public health…

A more social Europe needs a more robust Health Programme

The EU Civil Society Forum on HIV, TB and Hepatitis, gathering leading civil society organisations at the national and regional level in the EU and neighbouring countries, welcomes with caution the…

EATG 2017 annual report is out now

2017 was the year that marked 25 exciting years of HIV/AIDS activism for the European AIDS Treatment Group. A year working towards achieving our goals and objectives is condensed in…

Call for organisations and activists to present at the European NGO booth (world AIDS 2018 conference)

We are happy to invite organisations and activists in Europe and Central Asia to present, discuss, share and learn at European NGO booth at the world AIDS 2018 Amsterdam conference.…

EATG launches a report on access to HCV-related services in prison settings in Europe

Today, the European AIDS Treatment Group launches a report along with recommendations on access to HCV-related services in prison settings in Europe. At the same time, a pilot Spring European…

Gay activist Zak Kostopoulos lynched to death in Greece

The violent death of a well known gay activist in the Greek capital of Athens has shocked the local LGBT+ community, who are now demanding justice for 33-year-old Zak Kostopoulos.…

HIV i-Base: HIV Treatment Bulletin, 19 September 2018

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. In this issue of HTB: results from the UK HIV surveillance programme; AIDS 2018 – third reports; the…

EMA panel backs two new HIV drugs

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of two new oral treatments for adults with HIV-1 infection, Pifeltro and Delstrigo, both from Merck Sharp…

EMA: Companies stepping up efforts to ensure medicine supply post Brexit

Focus is now on 39 centrally authorised medicines, down from 108 The European Medicines Agency (EMA) has revised the number of centrally authorised medicines (CAPs) for which, based on current…

Source:
EMA
Read more...

Gilead subsidiary to launch authorized generics of Epclusa® and Harvoni® in the US

Gilead subsidiary to launch authorized generics of Epclusa® (sofosbuvir/velpatasvir) and Harvoni® (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C FOSTER CITY, Calif., Sep. 24, 2018-- Gilead Sciences, Inc.(NASDAQ: GILD) announced today…

Proof-of-concept HIV immunotherapy study passes Phase 1 safety trial

Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion…

Carotid artery atherosclerosis is associated with mortality in adults with HIV

Carotid artery plaque was predictive of mortality, with differences observed by sex and HIV serostatus, according to a study recently published in AIDS. B-mode ultrasound-based measures of the carotid artery predict…

Benefits of low-dose methotrexate in HIV patients unclear

In a phase 2 trial performed in older HIV-infected adults who have or are at an increased risk for atherosclerotic cardiovascular disease, low-dose methotrexate was associated with a significant decrease…

PrEP not tied to drug resistance

HIV-negative men who receive pre-exposure prophylaxis (PrEP) with tenofovir (TDF) and emtricitabine (FTC) do not develop resistance to these drugs, according to new findings from the IPERGAY ANRS trial. The…

Therapeutic vaccine effectively reduces viral load in chronic hepatitis B

In treatment-naïve patients with chronic hepatitis B virus (HBV) infection, a therapeutic vaccine candidate (NASVAC) more effectively reduced viral load compared with pegylated interferon (Peg-IFN), according to study results published…

Meta-analysis shows hepatitis C treatment is highly effective for drug users

Direct-acting antiviral treatment is highly effective at curing hepatitis C in people who inject drugs and in people receiving opioid substitution therapy, a systematic review and meta-analysis of 38 studies…

Hepatitis C elimination in people who inject drugs needs a health system strategy, says expert review

Achieving the elimination of hepatitis C in people who inject drugs will require a comprehensive health system-wide strategy that addresses stigma, barriers to care, financing, the involvement of people who…

Zoledronic acid is more effective than switching from tenofovir in HIV-positive people with low bone mineral density

Two infusions of zoledronic acid resulted in significantly greater increases in bone mineral density over 24 months than switching from tenofovir disoproxil fumarate (TDF) in virologically suppressed, HIV-positive adults with…

Racial segregation associated with new HIV infections among black heterosexuals living in the US

A greater degree of racial segregation in urban areas of the United States is associated with more new HIV infections among black heterosexual men and women, according to a study…

“I approached him when he was in his good moods”: how pregnant women introduce HIV self-tests to their partners

Providing HIV self-testing kits to pregnant women to encourage HIV testing in their male partners is acceptable to men and women in Uganda, but women who are apprehensive about their…

Aidspan publishes new issue of ‘Global Fund Observer’

Aidspan: Global Fund Observer Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, published Issue 342 of the ‘Global Fund Observer.’ The newsletter includes articles…

HIV treatment in Malta archaic, activist warns

Medication comes at a hefty price of €600 Treatment for human immunodeficiency virus (HIV) in Malta is “archaic” because doctors were prescribing “outdated” drug regiments, HIV awareness activist Mark Josef Rapa has…

US doctors’ organisation endorses event-based PrEP for the first time

For the first time, a US-based professional HIV body has published guidelines endorsing event-based or so-called ‘on-demand’ pre-exposure prophylaxis (PrEP) as an alternative to daily dosing. The International Antiviral Society-USA…

Cocrystal Pharma completes patient enrollment in Phase 2a study evaluating CC-31244 for ultra-short treatment of hepatitis C

ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication…

NIH launches study to test combination antibody treatment for HIV infection

A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institutes of Health. The early phase clinical trial will evaluate whether periodic…